VP-002

VP-002 is a development code identifying two distinct therapeutic assets. The first is a small-molecule antagonist of the C-C motif chemokine receptor 1 (CCR1), also known as BX471. Developed by Cycle Pharma and sponsored in clinical trials by Cancer Research Horizons, this version of VP-002 is designed to modulate the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) by inhibiting the recruitment and polarization of tumor-associated macrophages (TAMs). It is currently being evaluated in the Phase I/II CRISTAL-APC trial in combination with nab-paclitaxel and gemcitabine. The second asset, developed by Nuvara Therapeutics, is a Phase II anti-diarrheal and oral rehydration solution composed of a proprietary combination of prescription amino acids. This formulation is designed to treat infectious diarrhea and replace lost fluids by modulating epithelial transmembrane proteins, particularly in pediatric populations.

Other names

CCR1 antagonistCCR-1 antagonistCCR 1 antagonistBX471BX-471BX 471